TORONTO–(BUSINESS WIRE)–Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV:ATE,
OTCQB:ATBPF), a leader in developing safer therapeutics for pain and
inflammation, is pleased to announce that its Phase 2B dose-ranging,
efficacy study for ATB-346 has formally commenced. Enrollment is open,
clinical sites have been activated and patients will now begin screening.
The study is designed to validate the efficacy of ATB-346 in reducing
osteoarthritis (“OA”) pain and establish the dose for Phase 3
development. The study will involve a total of 360 patients with OA of
the knee, who will be randomized to placebo or one of three doses of
ATB-346 administered once daily: 150 mg, 200 mg or 250 mg.
“We are excited to officially commence the final Phase 2 study for
ATB-346,” commented Dan Legault, Antibe’s CEO. “A successful outcome in
this large clinical trial will further validate the best-in-class
potential of ATB-346, and will represent a major inflection point as we
position ourselves for Phase 3 development and global partnering
discussions.”
The study is being conducted by Veristat, Inc. (“Veristat”) in
approximately 35 clinical sites across Canada and is expected to have a
top-line data read-out this summer.
About ATB-346
ATB-346 is a hydrogen sulfide-releasing derivative of naproxen.
Nonsteroidal anti-inflammatory drugs (“NSAIDs”) are the most commonly
used therapy for osteoarthritis, but their use is associated with a high
incidence of gastrointestinal ulceration and bleeding. NSAIDs are also
widely used in conditions such as rheumatoid arthritis, ankylosing
spondylitis, gout, and general pain reduction, with a similarly high
rate of gastrointestinal ulceration and bleeding. It is well-accepted
that patients with these conditions would benefit greatly from an
effective, non-addictive, GI-sparing anti-inflammatory/analgesic agent
such as ATB-346.
About Antibe Therapeutics Inc.
Antibe develops safer, non-addictive medicines for pain and
inflammation. Antibe’s technology involves linking a hydrogen
sulfide-releasing molecule to an existing drug to produce a patented,
improved medicine. Antibe’s lead drug ATB-346 targets the global need
for a safer, non-addictive drug for chronic pain and inflammation.
ATB-352, the second drug in Antibe’s pipeline, targets the urgent global
need for a non-addictive analgesic for treating severe acute pain, while
ATB-340 is a GI-safe derivative of aspirin. www.antibethera.com.
Antibe’s subsidiary, Citagenix Inc. (“Citagenix”), is a leader in the
sales and marketing of tissue regenerative products servicing the
orthopedic and dental marketplaces. Since its inception in 1997,
Citagenix has become an important source of knowledge and experience for
bone regeneration in the Canadian medical device industry. Citagenix is
active in 15 countries, operating in Canada through its direct sales
teams, and internationally via a network of distributor partnerships. www.citagenix.com.
Forward Looking Information
This news release includes certain forward-looking statements, which may
include, but are not limited to, the completion of financing
transactions and the licensing and development of drugs and medical
devices. Any statements contained herein that are not statements of
historical facts may be deemed to be forward-looking, including those
identified by the expressions “will”, “anticipate”, “believe”, “plan”,
“estimate”, “expect”, “intend”, “propose” and similar expressions.
Forward-looking statements involve known and unknown risks and
uncertainties that could cause actual results, performance, or
achievements to differ materially from those expressed or implied in
this news release. Factors that could cause actual results to differ
materially from those anticipated in this news release include, but are
not limited to, the Company’s ability to secure additional financing,
its ability to execute its business strategy and successfully compete in
the market, and risks associated with drug and medical device
development generally. Antibe Therapeutics Inc. assumes no obligation to
update the forward-looking statements or to update the reasons why
actual results could differ from those reflected in the forward-looking
statements except as required by applicable law.
Contacts
Antibe Therapeutics Inc.
Dan Legault
Chief Executive Officer
(416)
473 4095
dan.legault@antibethera.com